product name Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate (also called MPA) is a steroidal progestin, a synthetic variant of the human hormone progesterone. It is used as a contraceptive, in hormone replacement therapy and for the treatment of endometriosis. Medroxyprogesterone acetate inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone and 3alpha, 5alpha-tetrahydroprogesterone.
References: J Neurobiol. 2006 Aug;66(9):916-28; Thyroid. 2003;13(3):249-58; Neurobiol Learn Mem. 2010;93(3):444-53.
386.52
Formula
C24H34O4
CAS No.
71-58-9
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 12 mg/mL (31.0 mM)
Water: <1 mg/mL
Ethanol: 12 mg/mL warmed (31.0 mM)
Solubility (In vivo)
Synonyms
NSC-26386
other peoduct :References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/19418094
| In Vitro |
In vitro activity: Medroxyprogesterone acetate (MPA) inhibits the enzyme 3-hydroxyste-roid dehydrogenase, involved in the reversible conversion between 5alpha-dihydroprogesterone (DHP) and 3alpha, 5alpha-tetrahydroprogesterone (THP), and therefore may affect the local actions of DHP and THP in the brain. Medroxyprogesterone acetate (MPA) reduces secretion of IL-6 and PTHrP from human breast cancer cells. MPA dose-dependently decreases the secretion and mRNA expression of IL-6 and PTHrP in the KTC-2 cells. Medroxyprogesterone acetate (MPA) and dexamethasone dose dependently increases alpha-ENaC promoter-driven luciferase activity in M-1 cells, which is not inhibited by Org31710, indicating that Medroxyprogesterone acetate regulates alpha-ENaC in a PR-independent manner. Medroxyprogesterone acetate and dexamethasone, but not progesterone, dose dependently increases alpha-ENaC and sgk1 mRNA in M-1 and in Madin-Darby canine kidney-C7 cells, both collecting duct cell lines. Medroxyprogesterone acetate (MPA) (0.1 nM) significantly enhances the in vitro production of specific immunoglobulin G (IgG) antibodies, an effect that appears to involve the interaction of the progestin with PRG receptors. Kinase Assay: Cell Assay: |
|---|---|
| In Vivo | Medroxyprogesterone acetate (MPA) impairs delayed memory retention on the water radial-arm maze (WRAM), and exacerbates overnight forgetting on the Morris maze (MM) in aged ovariectomized (OVX) rats. Medroxyprogesterone acetate (MPA) significantly and progesterone marginally decreases GAD levels in the hippocampus, and both MPA and progesterone significantly increases GAD levels in the entorhinal cortex. |
| Animal model | |
| Formulation & Dosage | |
| References | J Neurobiol. 2006 Aug;66(9):916-28; Thyroid. 2003 Mar;13(3):249-58; Neurobiol Learn Mem. 2010 Mar;93(3):444-53. |
